Gumokimab (AK 111) is a monoclonal antibody targeting IL-17A, which can be used in the study of psoriasis, ankylosing spondylitis. Gumokimab competitively blocks the binding of human IL-17A to IL-17R .

2023年12月1日， 康方生物 （9926.HK）宣布公司自主研发的新型人源化IL-17单克隆抗体古莫奇单抗（AK111）治疗中、重度斑块型银屑病的关键注册性Ⅲ期临床研究达到包括PASI100 …

USS Giansar (AK-111) was a Crater-class cargo ship originally laid down as the liberty ship SS Thomas Ewing. The ship was taken over by the United States Navy and renamed in 1943. After being decommissioned in 1945, Giansar was returned to the Maritime Commission .

2024年4月20日 · AK-111（gumokimab）是由康方生物开发的靶向IL-17的单抗，用于治疗银屑病和AS，银屑病适应症处于国内NDA阶段，有官方记录最早时间为2016年11月处于临床前阶段，2018年10月进入临床I期阶段，2021年4月进入临床II期阶段，2022年8月进入临床III期阶段。

AK-111;AK111;AK 111. Synonyms: IL17;CTLA8;IL-17;ILA17;CTLA-8;IL-17A. Applications: N/A. Recommended Dilutions: N/A. Formulation & Reconstitution: Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution. Host ...

Gumokimab (AK 111) 是靶向 IL-17A 的单克隆抗体，可用于银屑病、强直性脊柱炎的研究。 Gumokimab 能够竞争性阻断人 IL-17A 与 IL-17R 的结合。 立即从AbMole中国订购高品质IL Receptor/Related抑制剂Gumokimab！

Gumokimab(AK 111)是一种针对IL-17A的单克隆抗体,可用于银屑病、强直性脊柱炎的研究。Gumokimab竞争性地阻断人IL-17A与IL-17R的结合。

ak-111注射液，是由中山康方生物医药有限公司进行申报，采用随机化双盲的安全性和有效性，了解更多关于ak-111注射液临床试验信息。 AK-111注射液临床Ⅱ期随机化双盲试验_摩熵医药(原药融云)

AK111 is a new monoclonal antibody, a new drug candidate developed in-house by the Company against the second-generation autoimmune disease target IL-17, and is designed to treat psoriasis, ankylosing spondylitis (AS) and axial spondylitis (axSpA). Phase 3: Psoriasis|Spondylarthritis|Spondylitis, Ankylosing. Phase 2: Spondyloarthritis.